|
|
Analysis of the Development Trend of Targeted Protein Degradation Technology |
SHI Huilin,LI Wei,JIN Chenqi,XU Ping,WANG Yue**() |
Shanghai Information Center for Life Sciences, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai 200031, China |
|
|
Abstract Targeted protein degradation (TPD) technology refers to a type of technology that utilizes the internal naturally occurring protein purification system to reduce target protein levels. By analyzing the status of basic research and industrial development status of TPD, it can be seen that the development of TPD has entered the fast lane in recent years. With the progress of research, the resources of degradable target protein and recruitable E3 ubiquitin ligase have been expanded, and the stability and efficacy of TPD have been further improved, which realizes controllable and precise degradation. At the same time, the target protein has been expanded from intracellular proteins to extracellular and membrane-binding proteins, protein aggregates, and non-protein substances such as RNA, lipids, organelles, and pathogens based on technological prototype innovation. TPD technology has also provided new ideas for the development of new drugs against undruggable targets, ushering in a new wave in the pharmaceutical industry, and opening up new avenues for the treatment of diseases such as cancer and autoimmune diseases.
|
Received: 24 May 2023
Published: 03 April 2024
|
|
|
|
[1] |
Sakamoto K M, Kim K B, Kumagai A, et al. Protacs:chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98(15): 8554-8559.
|
|
|
[2] |
Schneekloth A R, Pucheault M, Tae H S, et al. Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics. Bioorganic & Medicinal Chemistry Letters, 2008, 18(22): 5904-5908.
doi: 10.1016/j.bmcl.2008.07.114
|
|
|
[3] |
He M, Cao C G, Ni Z H, et al. PROTACs: great opportunities for academia and industry (an update from 2020 to 2021). Signal Transduction and Targeted Therapy, 2022, 7: 181.
doi: 10.1038/s41392-022-00999-9
pmid: 35680848
|
|
|
[4] |
Donovan K A, Ferguson F M, Bushman J W, et al. Mapping the degradable kinome provides a resource for expedited degrader development. Cell, 2020, 183(6): 1714-1731.e10.
doi: 10.1016/j.cell.2020.10.038
pmid: 33275901
|
|
|
[5] |
Schneider M, Radoux C J, Hercules A, et al. The PROTACtable genome. Nature Reviews Drug Discovery, 2021, 20: 789-797.
doi: 10.1038/s41573-021-00245-x
pmid: 34285415
|
|
|
[6] |
C4 Therapeutics. C4 therapeutics presents pre-clinical data on CFT8919, a selective degrader of EGFR L858R, at keystone symposium on targeted protein degradation. [2023-04-20]. https://ir.c4therapeutics.com/news-releases/news-release-details/c4-therapeutics-presents-pre-clinical-data-cft8919-selective.
|
|
|
[7] |
Bond M J, Chu L, Nalawansha D A, et al. Targeted degradation of oncogenic KRAS(G12C) by VHL-recruiting PROTACs. ACS Central Science, 2020, 6(8): 1367-1375.
doi: 10.1021/acscentsci.0c00411
|
|
|
[8] |
Bond M J, Crews C M. Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation. RSC Chemical Biology, 2021, 2(3): 725-742.
doi: 10.1039/d1cb00011j
pmid: 34212149
|
|
|
[9] |
Weagel E G, Foulks J M, Siddiqui A, et al. Molecular glues: enhanced protein-protein interactions and cell proteome editing. Medicinal Chemistry Research, 2022, 31(7): 1068-1087.
doi: 10.1007/s00044-022-02882-2
|
|
|
[10] |
Jevtic P, Haakonsen D L, Rapé M, et al. An E3 ligase guide to the galaxy of small-molecule-induced protein degradation. Cell Chemical Biology, 2021, 28(7): 1000-1013.
doi: 10.1016/j.chembiol.2021.04.002
|
|
|
[11] |
Lv D W, Pal P, Liu X G, et al. Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity. Nature Communications, 2021, 12: 6896.
doi: 10.1038/s41467-021-27210-x
pmid: 34824248
|
|
|
[12] |
Imaide S, Riching K M, Makukhin N, et al. Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity. Nature Chemical Biology, 2021, 17: 1157-1167.
doi: 10.1038/s41589-021-00878-4
pmid: 34675414
|
|
|
[13] |
Yang Z M, Sun Y H, Ni Z H, et al. Merging PROTAC and molecular glue for degrading BTK and GSPT1 proteins concurrently. Cell Research, 2021, 31: 1315-1318.
doi: 10.1038/s41422-021-00533-6
pmid: 34417569
|
|
|
[14] |
Cotton A D, Nguyen D P, Gramespacher J A, et al. Development of antibody-based PROTACs for the degradation of the cell-surface immune checkpoint protein PD-L1. Journal of the American Chemical Society, 2021, 143(2): 593-598.
doi: 10.1021/jacs.0c10008
pmid: 33395526
|
|
|
[15] |
Marei H, Tsai W T K, Kee Y S, et al. Antibody targeting of E3 ubiquitin ligases for receptor degradation. Nature, 2022, 610: 182-189.
doi: 10.1038/s41586-022-05235-6
|
|
|
[16] |
Pance K, Gramespacher J A, Byrnes J R, et al. Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins. Nature Biotechnology, 2023, 41: 273-281.
doi: 10.1038/s41587-022-01456-2
|
|
|
[17] |
Xue G, Wang K, Zhou D L, et al. Light-induced protein degradation with photocaged PROTACs. Journal of the American Chemical Society, 2019, 141(46): 18370-18374.
doi: 10.1021/jacs.9b06422
pmid: 31566962
|
|
|
[18] |
Pfaff P, Samarasinghe K T G, Crews C M, et al. Reversible spatiotemporal control of induced protein degradation by bistable PhotoPROTACs. ACS Central Science, 2019, 5(10): 1682-1690.
doi: 10.1021/acscentsci.9b00713
pmid: 31660436
|
|
|
[19] |
Cheng W Y, Li S S, Wen X Q, et al. Development of hypoxia-activated PROTAC exerting a more potent effect in tumor hypoxia than in normoxia. Chemical Communications, 2021, 57(95): 12852-12855.
doi: 10.1039/d1cc05715d
pmid: 34788776
|
|
|
[20] |
Liang C J, Zheng Q Z, Luo T L, et al. Enzyme-catalyzed activation of pro-PROTAC for cell-selective protein degradation. CCS Chemistry, 2022, 4(12): 3809-3819.
doi: 10.31635/ccschem.022.202101529
|
|
|
[21] |
Zhou Y X, Teng P, Montgomery N T, et al. Development of triantennary N-acetylgalactosamine conjugates as degraders for extracellular proteins. ACS Central Science, 2021, 7(3): 499-506.
doi: 10.1021/acscentsci.1c00146
pmid: 33791431
|
|
|
[22] |
Liu J, Chen H, Liu Y, et al. Cancer selective target degradation by folate-caged PROTACs. Journal of the American Chemical Society, 2021, 143(19): 7380-7387.
doi: 10.1021/jacs.1c00451
pmid: 33970635
|
|
|
[23] |
Gao J, Hou B, Zhu Q W, et al. Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy. Nature Communications, 2022, 13: 4318.
doi: 10.1038/s41467-022-32050-4
pmid: 35882867
|
|
|
[24] |
He S P, Gao F, Ma J H, et al. Aptamer-PROTAC conjugates (APCs) for tumor-specific targeting in breast cancer. Angewandte Chemie (International Ed in English), 2021, 60(43): 23299-23305.
doi: 10.1002/anie.v60.43
|
|
|
[25] |
Ahn G, Banik S M, Miller C L, et al. LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation. Nature Chemical Biology, 2021, 17: 937-946.
doi: 10.1038/s41589-021-00770-1
pmid: 33767387
|
|
|
[26] |
Morreale F E, Kleine S, Leodolter J, et al. BacPROTACs mediate targeted protein degradation in bacteria. Cell, 2022, 185(13): 2338-2353.e18.
doi: 10.1016/j.cell.2022.05.009
pmid: 35662409
|
|
|
[27] |
刘少金, 窦树珍, 王俊姝, 等. 靶向蛋白降解药物市场分析及建议. 中国生物工程杂志, 2023, 43(S1): 190-200.
|
|
|
[27] |
Liu S J, Dou S Z, Wang J S, et al. Market analysis and suggestions of targeted protein degradation drugs. China Biotechnology, 2023, 43(S1): 190-200.
|
|
|
[28] |
Zheng S J, Tan Y H, Wang Z Y, et al. Accelerated rational PROTAC design via deep learning and molecular simulations. Nature Machine Intelligence, 2022, 4: 739-748.
doi: 10.1038/s42256-022-00527-y
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|